Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Mini Rev Med Chem ; 21(9): 1048-1057, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33390131

RESUMO

Thiazolo- and thiadiazolo-[3,2-a][1,3]diazepines and their patented derivatives, tested with diverse CNS pharmacological activities, constitute an important class of compounds for new drug development. Therefore, research efforts were continued to design, synthesize, and evaluate compounds for their ultra-short, short-acting hypnotic, anticonvulsant, and neuromuscular blocking activities. The present review provides a summary of the work accomplished by these heterocycles and their biological evaluation.


Assuntos
Anticonvulsivantes/farmacologia , Azepinas/farmacologia , Agonistas de Receptores de GABA-A/farmacologia , Bloqueadores Neuromusculares/farmacologia , Receptores de GABA-A/metabolismo , Tiazóis/farmacologia , Animais , Anticonvulsivantes/química , Azepinas/química , Agonistas de Receptores de GABA-A/química , Humanos , Modelos Moleculares , Estrutura Molecular , Bloqueadores Neuromusculares/química , Tiazóis/química
2.
Sleep Med ; 52: 213-218, 2018 12.
Artigo em Inglês | MEDLINE | ID: mdl-30097333

RESUMO

OBJECTIVE: Most previous studies have concluded that decreased cognitive function and performance due to ultra-short acting hypnotics do not persist after 6-9 h post-administration. This study examined the effects of ultra-short acting hypnotics on cognitive function and performance 12 h after administration, ie, a time considered sufficient for the effects of hypnotics to disappear. METHODS: Thirteen healthy young male volunteers (mean age, 23.4 ± 3.2 years) participated in this study. Participants attended three sessions of polysomnography (PSG) recording preceded by oral administration of placebo for the first session, and 5 mg zolpidem or 0.25 mg triazolam for the second and third sessions, in a double-blinded, randomized manner at intervals of at least five days. A cognitive test battery was administered following each session, consisting of a psychomotor vigilance task (PVT), which reflects alertness and sleepiness, digit symbol substitution test (DSST), which reflects attention and working memory function, and assessment of subjective sleepiness and mental condition using a visual analog scale (VAS). RESULTS AND CONCLUSIONS: The administration of hypnotics significantly increased total sleep time, sleep efficiency, and sleep stages 2 and 4, and significantly decreased wake after sleep onset and sleep stage 1. PVT parameters were not affected by the administration of hypnotics, but DSST score was significantly lower, and "subjective alertness," "vigor," and "sadness" significantly deteriorated, after administration. In conclusion, while objective sleepiness disappeared 12 h after the administration of ultra-short acting hypnotics, their effects to decrease cognitive function persisted even after 12 h post-administration.


Assuntos
Ansiolíticos/farmacologia , Cognição/efeitos dos fármacos , Testes Neuropsicológicos/estatística & dados numéricos , Medicamentos Indutores do Sono/farmacologia , Triazolam/farmacologia , Zolpidem/farmacologia , Adulto , Humanos , Masculino , Polissonografia , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA